Lumos Pharma, Inc. (LUMO)
LUMO moved a median of 0.00% 30 minutes after news, and -0.23% by the close. How LUMO actually reacts to news — the realized, point-in-time move the market made, measured across 123 labeled events over the last three years with zero look-ahead.
LUMO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 26% | 70 |
| 30-min | 0.00% | 40% | 83 |
| 60-min | -0.23% | 44% | 85 |
| to close | -0.23% | 40% | 86 |
| Middle 50% of LUMO reactions | -0.66% to +0.84% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 123 |
Half of all Lumos Pharma, Inc. news events land between -0.66% and +0.84% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when LUMO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LUMO's baseline. Nothing else.
Recent LUMO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G LUMOS PHARMA, INC. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form AW LUMOS PHARMA, INC. | SEC filing · Form AW | SEC EDGAR | — | — | |
| Form EFFECT LUMOS PHARMA, INC. | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K LUMOS PHARMA, INC. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM LUMOS PHARMA, INC. | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS LUMOS PHARMA, INC. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma | Press release | GlobeNewswire | — | — | |
| Form 8-K LUMOS PHARMA, INC. For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | -1.16% | +0.00% | |
| Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action | Press release | GlobeNewswire | +0.12% | +0.23% | |
| Form 10-Q LUMOS PHARMA, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +0.35% | |
| Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62n? Annual ESPE Meeting 2024 | Press release | GlobeNewswire | +0.46% | +2.78% | |
| ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc. | Press release | PR Newswire | -0.69% | -0.23% | |
| Form 8-K LUMOS PHARMA, INC. For: Oct 22 | SEC filing · Form 8-K | SEC EDGAR | +2.04% | -1.13% | |
| LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders | Press release | Business Wire | +0.46% | -0.46% | |
| Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) | Press release | GlobeNewswire | +2.04% | -1.13% | |
| Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024 | Press release | GlobeNewswire | -0.97% | -6.57% | |
| Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024 | Press release | GlobeNewswire | -2.26% | -4.51% | |
| Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | -1.21% | |
| Form 10-Q LUMOS PHARMA, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.89% | +1.63% | |
| Form 8-K LUMOS PHARMA, INC. For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | -4.89% | +1.63% | |
| Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update | Press release | GlobeNewswire | -4.89% | +1.63% | |
| Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024 | Press release | GlobeNewswire | — | +2.61% | |
| Form 8-K LUMOS PHARMA, INC. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | — | +7.72% | |
| Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | Press release | GlobeNewswire | — | -1.30% | |
| Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024 | Press release | GlobeNewswire | -3.83% | -3.45% | |
| Form 10-Q LUMOS PHARMA, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.03% | +18.47% | |
| Form 8-K LUMOS PHARMA, INC. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.28% | |
| Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results | Press release | GlobeNewswire | +0.00% | -8.57% | |
| Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 | Press release | GlobeNewswire | -0.17% | +0.00% | |
| Form 10-K/A LUMOS PHARMA, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.73% | +1.82% | |
| Form 8-K LUMOS PHARMA, INC. For: Apr 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.26% | |
| Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings | Press release | GlobeNewswire | +0.00% | -2.26% | |
| Form ARS LUMOS PHARMA, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +2.44% | |
| Form DEF 14A LUMOS PHARMA, INC. For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +6.09% | +1.24% | |
| Form DEFA14A LUMOS PHARMA, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +6.09% | +1.24% | |
| Form 8-K LUMOS PHARMA, INC. For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | — | -1.02% | |
| Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 | Press release | GlobeNewswire | -3.64% | +8.52% | |
| Form 10-K LUMOS PHARMA, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.69% | +2.01% | |
| Form 8-K LUMOS PHARMA, INC. For: Mar 07 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | +2.01% | |
| Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update | Press release | GlobeNewswire | +0.69% | +2.01% | |
| Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024 | Press release | GlobeNewswire | +0.00% | +4.11% | |
| Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | — | -1.95% | |
| Form 8-K LUMOS PHARMA, INC. For: Jan 04 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.58% | |
| Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer | Press release | GlobeNewswire | +0.00% | +4.58% | |
| Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency | Press release | GlobeNewswire | +0.00% | +2.67% | |
| Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November | Press release | GlobeNewswire | +0.00% | +3.04% | |
| Form 8-K LUMOS PHARMA, INC. For: Nov 15 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | -0.99% | |
| Form 10-Q LUMOS PHARMA, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.34% | -9.44% | |
| Form 8-K LUMOS PHARMA, INC. For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -4.34% | -9.44% | |
| Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints | Press release | GlobeNewswire | -4.34% | -9.44% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LUMO section they belong to.
Where else LUMO is measured.
LUMO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lumos Pharma, Inc.'s median reaction calculated?
Every labeled LUMO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 123 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of LUMO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LUMO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.